Author(s): Rohan Mishra, Aneesh T P

Email(s): aneesh21atp@gmail.com

DOI: 10.52711/0974-360X.2021.00774   

Address: Rohan Mishra, Aneesh T P*
Amrita School of Pharmacy, Amrita Vishwa Vidyapeetham, AIMS Health Sciences Campus, Kochi, Kerala - 682041, India.
*Corresponding Author

Published In:   Volume - 14,      Issue - 8,     Year - 2021


ABSTRACT:
Over the last few decades, either the single-pill therapy or the combinations of pill therapy were at the cutting edge in drug design and development processes, which not only proved to have treated innumerable complications but also have proved its drastic need in the past and even in the present watch. This review has a briefing on the comparison of the different aspects of prescriptions as polypharmacy, combination therapy along with multi targets drugs. As the time passed, the need for an alternative to overcome the several possible ill-effects like drug-drug interaction, non-adherence, fixed-dose medications for all patients, etc., also have paved the way to showcase the in-efficiency in treating the complex nexus cascade that has raised a thought amongst for a newer brand new perspective to take a turn and transmute the concept of drug design. From a single targeted therapy to a multi-targeted approach in this drug design pattern. It also mentions the colligation of different pharmacophores entities to obtain a better potent drug with better ADMET. An overview of how 'efficient, relevant, and important multi-target drug therapy would be over a combination of pills' further have been sketched and depicted based on past prototype examples and present scenarios. The feasibility of the concept was investigated by an in silico approach where a colligated molecule of tranexamic acid and Meloxicam was analysed for its binding affinity towards the parent receptors. The newly designed, the colligated molecule was found to be more active than the parent drugs to multiple targets. The evaluation of the concept leads to a new horizon of MTD, which can be adopted through several approaches, including the colligation of the already existing drugs.


Cite this article:
Rohan Mishra, Aneesh T P. Combination Vs. Multi-target drugs: The Clash of the titans in the arena of drug discovery; An overview and in silico evaluation. Research Journal of Pharmacy and Technology. 2021; 14(8):4455-2. doi: 10.52711/0974-360X.2021.00774

Cite(Electronic):
Rohan Mishra, Aneesh T P. Combination Vs. Multi-target drugs: The Clash of the titans in the arena of drug discovery; An overview and in silico evaluation. Research Journal of Pharmacy and Technology. 2021; 14(8):4455-2. doi: 10.52711/0974-360X.2021.00774   Available on: https://rjptonline.org/AbstractView.aspx?PID=2021-14-8-80


REFERENCES:
1.    Billing U, Jetka T, Nortmann L, Wundrack N, Komorowski M, Waldherr S, et al. Robustness and Information Transfer within IL-6-induced JAK/STAT Signalling. Commun Biol [Internet]. 2019; 2(1): 1–14. Available from: http://dx.doi.org/10.1038/s42003-018-0259-4
2.    Lokau J, Schoeder V, Haybaeck J, Garbers C. Jak-stat signaling induced by interleukin-6 family cytokines in hepatocellular carcinoma. Cancers (Basel). 2019; 11(11): 1–17.
3.    Rosini M. Polypharmacology: The rise of multi-target drugs over combination therapies. Future Med Chem. 2014; 6(5): 485–7.
4.    Sica DA. Fixed-dose combination antihypertensive drugs: Principles and practice. Cardiovasc Rev Reports. 1997; 18(9): 28–46.
5.    Gupta A, Rawat S, Gupta P. Pharmacoepidemiology of Severe Systemic Infection and Need of Netilmicin Monotherapy or Combination Therapy: Systemic Review and Meta-Analysis. Res J Pharm Dos Forms Technol [Internet]. 2017 Sep 30 [cited 2020 Sep 9]; 9(3): 101. Available from: https://rjpdft.com/AbstractView.aspx?PID=2017-9-3-4
6.    Rajashekar S, Abimanyu S. Risk and Opportunities in Development of New Drug. Res J Pharm Technol [Internet]. 2020 Jun 23 [cited 2020 Sep 9];13(6):3041. Available from: https://rjptonline.org/AbstractView.aspx?PID=2020-13-6-90
7.    Pandi Kumar V, Prasanna V, Shanmugasundaram P. A prospective study on comparing the efficacy of combination therapy and monotherapy of DMARDS in patients with rheumatoid arthritis. Res J Pharm Technol [Internet]. 2018 Oct 1 [cited 2020 Sep 9]; 11(10): 4497–501. Available from: https://rjptonline.org/AbstractView.aspx?PID=2018-11-10-53
8.    Sharma D, Mehta DK, Bhatti K, Das R, Chidurala RM. Amlodipine and Atenolol: Combination Therapy Versus Monotherapy In Reducing Blood Pressure -A Focus On Safety And Efficacy. Res J Pharm Technol [Internet]. 2020 Jun 23 [cited 2020 Sep 9];13(6):3007. Available from: https://rjptonline.org/AbstractView.aspx?PID=2020-13-6-85
9.    Bolognesi ML, Cavalli A, Melchiorre C. Memoquin: A Multi-Target-Directed Ligand as an Innovative Therapeutic Opportunity for Alzheimer's Disease. Neurotherapeutics. 2009; 6(1): 152–62.
10.    Polypharmacy and Inappropriate Drug Use among Older Peopleandmdash;a Systematic Review. Heal Aging Clin Care Elder. 2013; 5: 1–8.
11.    Davies LE, Spiers G, Kingston A, Todd A, Adamson J, Hanratty B. Adverse Outcomes of Polypharmacy in Older People: Systematic Review of Reviews. J Am Med Dir Assoc. 2020; 21(2): 181–7.
12.    Giordano S, Petrelli A. From Single- to Multi-Target Drugs in Cancer Therapy: When Aspecificity Becomes an Advantage. Curr Med Chem. 2008; 15(5): 422–32.
13.    Morphy R, Kay C, Rankovic Z. From magic bullets to designed multiple ligands. Drug Discov Today. 2004; 9(15): 641–51.
14.    Talevi A. Multi-target pharmacology: Possibilities and limitations of the "skeleton key approach" from a medicinal chemist perspective. Front Pharmacol. 2015; 6(SEP): 1–7.
15.    Skok Ž, Zidar N, Kikelj D, Ilaš J. Dual Inhibitors of Human DNA Topoisomerase II and Other Cancer-Related Targets. J Med Chem. 2020; 63(3): 884–904.
16.    Ramsay RR, Popovic-Nikolic MR, Nikolic K, Uliassi E, Bolognesi ML. A perspective on multi-target drug discovery and design for complex diseases. Clin Transl Med [Internet]. 2018; 7(1). Available from: https://doi.org/10.1186/s40169-017-0181-2
17.    de Castro S, Camarasa MJ. Polypharmacology in HIV inhibition: can a drug with simultaneous action against two relevant targets be an alternative to combination therapy? Eur J Med Chem. 2018; 150: 206–27.
18.    Li YH, Wang PP, Li XX, Yu CY, Yang H, Zhou J, et al. The human kinome targeted by FDA approved multi-target drugs and combination products: A comparative study from the drug-target interaction network perspective. PLoS One. 2016; 11(11): 1–15.
19.    Lin HH, Zhang L Le, Yan R, Lu JJ, Hu Y. Network Analysis of Drug-target Interactions: A Study on FDA-approved New Molecular Entities between 2000 to 2015. Sci Rep [Internet]. 2017;7(1):1–9. Available from: http://dx.doi.org/10.1038/s41598-017-12061-8
20.    Hopkins AL. Network pharmacology: The next paradigm in drug discovery. Nat Chem Biol. 2008; 4(11): 682–90.
21.    Jia J, Zhu F, Ma X, Cao ZW, Li YX, Chen YZ. Mechanisms of drug combinations: Interaction and network perspectives. Nat Rev Drug Discov. 2009; 8(2): 111–28.
22.    Zimmermann GR, Lehár J, Keith CT. Multi-target therapeutics: when the whole is greater than the sum of the parts. Drug Discov Today. 2007; 12(1–2): 34–42.
23.    Wagner H. Multitarget therapy - The future of treatment for more than just functional dyspepsia. Phytomedicine. 2006; 13(SUPPL. 1): 122–9.
24.    Peters J-U. Designing Multi-Target Drugs. Edited by J. Richard Morphy and C. John Harris. Chem Med Chem. 2013; 8(1): 166–7.
25.    Scotti L, Mendonca Junior F, Ishiki H, Ribeiro F, Singla R, Filho J, et al. Docking Studies for Multi-Target Drugs. Curr Drug Targets. 2015; 18(5): 592–604.
26.    Méndez-Lucio O, Naveja JJ, Vite-Caritino H, Prieto-Martínez FD, Medina-Franco JL. Review. One drug for multiple targets: A computational perspective. J Mex Chem Soc. 2016; 60(3): 168–81.
27.    Bharati D, Jagtap R, Kanase K, Sonawame S, Undale V, Bhosale A. Chemo informatics: Newer Approach for Drug Development. Asian J Res Chem. 2009; 2(1):1–7.
28.    Lohith TN, Kumar L, Verma R. Design, molecular docking, ADME analysis and molecular dynamics studies of novel acetylated schiff bases as COX-2 inhibitors. Res J Pharm Technol [Internet]. 2020 Apr 1 [cited 2020 Sep 9];13(4): 1899–904. Available from: https://rjptonline.org/AbstractView.aspx?PID=2020-13-4-52
29.    Misra PS, Ravichandiran V, Vijey Aanandhi M. Design, synthesis and in silico molecular docking study of n-carbamoyl-6-oxo-1-phenyl-1, 6-dihydropyridine-3-carboxamide derivatives as fibroblast growth factor 1 inhibitor. Res J Pharm Technol [Internet]. 2017 Aug 1 [cited 2020 Sep 9];10(8):2527–34. Available from: https://rjptonline.org/AbstractView.aspx?PID=2017-10-8-17
30.    Dencelinx L, Ramkumar T. Distributed machine learning algorithms to classify protein secondary structures for drug design – a survey. Res J Pharm Technol [Internet]. 2017 Sep 1 [cited 2020 Sep 9]; 10(9): 3173–80. Available from: https://rjptonline.org/AbstractView.aspx?PID=2017-10-9-64
31.    Valluri KK, Allaka TR, Viswanath IVK, Nagaraju P. Design, molecular docking studies of oxaprozin linked to 4-Thiazolidinone derivatives as a potent anticancer, analgesic and antiinflammatory agents. Asian J Res Chem [Internet]. 2018 Jun 30 [cited 2020 Sep 9];11(3):617. Available from: https://ajrconline.org/AbstractView.aspx?PID=2018-11-3-20
32.    Baul HS, Rajiniraja M. Molecular docking studies of selected flavonoids on inducible nitric oxide synthase (INOs) in parkinson's disease. Res J Pharm Technol [Internet]. 2018 Aug 1 [cited 2020 Sep 9];11(8):3685–8. Available from: https://rjptonline.org/AbstractView.aspx?PID=2018-11-8-81

Recomonded Articles:

Research Journal of Pharmacy and Technology (RJPT) is an international, peer-reviewed, multidisciplinary journal.... Read more >>>

RNI: CHHENG00387/33/1/2008-TC                     
DOI: 10.5958/0974-360X 

0.38
2018CiteScore
 
56th percentile
Powered by  Scopus


SCImago Journal & Country Rank


Recent Articles




Tags


Not Available